Bioxytran, Inc. (OTCMKTS:BIXT) Sees Large Increase in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 14,198 shares, an increase of 4,632.7% from the April 30th total of 300 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 81,682 shares, the days-to-cover ratio is currently 0.2 days.

Bioxytran Price Performance

BIXT opened at $0.03 on Thursday. Bioxytran has a fifty-two week low of $0.03 and a fifty-two week high of $0.16. The company’s 50 day moving average price is $0.04 and its two-hundred day moving average price is $0.05. The firm has a market capitalization of $3.43 million, a price-to-earnings ratio of -1.50 and a beta of 1.95.

Bioxytran (OTCMKTS:BIXT) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.02) EPS for the quarter.

About Bioxytran

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.